On Feb. 25, President Donald Trump signed an executive order targeted at boosting healthcare price transparency.
The order directs HHS and the Labor and Treasury departments to “rapidly implement and enforce” healthcare price transparency enforcement regulations. The order refers to regulations that President Trump introduced during his first term, which he said the Biden administration was “slow walking,” according to a Feb. 25 White House fact sheet.
Roger Corle, CEO of Prologics in Franklin, Tenn., joined Becker’s to share his thoughts on price transparency and how it may impact patients and the ASC industry.
Editor’s note: Responses have been lightly edited for clarity and length:
Roger Corle: Progress in price transparency continues to be a good thing for consumers and healthcare in general. It has been a slow process and can still be opaque for patients but is moving in the right direction so that patients can make better-informed decisions about where they receive their care and have a clearer understanding of what their costs will be. Not only does price transparency benefit the consumer, but also benefits ASCs as it highlights the price discrepancy between hospitals and ASCs for the same surgeries. Hospitals are aware of this and don’t make it easy for consumers to interpret this information. Payers are even [more] veiled regarding the rates they pay hospitals as well as other providers. Our team at Prologics Healthcare works with ASCs and physician groups around the country to assist them in deciphering hospital price transparency and machine-readable payer price transparency files, and can greatly assist them in negotiating higher reimbursement with payers in their respective markets.
The post A ‘move in the right direction’ for price transparency appeared first on Becker’s ASC.
